Thieulent, C.J.; Sutton, G.; Toquet, M.-P.; Fremaux, S.; Hue, E.; Fortier, C.; Pléau, A.; Deslis, A.; Abrioux, S.; Guitton, E.;
et al. Oral Administration of Valganciclovir Reduces Clinical Signs, Virus Shedding and Cell-Associated Viremia in Ponies Experimentally Infected with the Equid Herpesvirus-1 C2254 Variant. Pathogens 2022, 11, 539.
https://doi.org/10.3390/pathogens11050539
AMA Style
Thieulent CJ, Sutton G, Toquet M-P, Fremaux S, Hue E, Fortier C, Pléau A, Deslis A, Abrioux S, Guitton E,
et al. Oral Administration of Valganciclovir Reduces Clinical Signs, Virus Shedding and Cell-Associated Viremia in Ponies Experimentally Infected with the Equid Herpesvirus-1 C2254 Variant. Pathogens. 2022; 11(5):539.
https://doi.org/10.3390/pathogens11050539
Chicago/Turabian Style
Thieulent, Côme J., Gabrielle Sutton, Marie-Pierre Toquet, Samuel Fremaux, Erika Hue, Christine Fortier, Alexis Pléau, Alain Deslis, Stéphane Abrioux, Edouard Guitton,
and et al. 2022. "Oral Administration of Valganciclovir Reduces Clinical Signs, Virus Shedding and Cell-Associated Viremia in Ponies Experimentally Infected with the Equid Herpesvirus-1 C2254 Variant" Pathogens 11, no. 5: 539.
https://doi.org/10.3390/pathogens11050539
APA Style
Thieulent, C. J., Sutton, G., Toquet, M.-P., Fremaux, S., Hue, E., Fortier, C., Pléau, A., Deslis, A., Abrioux, S., Guitton, E., Pronost, S., & Paillot, R.
(2022). Oral Administration of Valganciclovir Reduces Clinical Signs, Virus Shedding and Cell-Associated Viremia in Ponies Experimentally Infected with the Equid Herpesvirus-1 C2254 Variant. Pathogens, 11(5), 539.
https://doi.org/10.3390/pathogens11050539
